FDMT
4D Molecular Therapeutics, Inc.
Biotechnology · Healthcare · United States
11.90
close · 2026-10-30
value
40
cheaper than peers40
quality
74
stronger fundamentals74
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.61× | 78 |
| price to sales | 7.45× | 60 |
| earnings yield, 2 years ago | -21.7% | 45 |
| cash flow yield, 2 years ago | -12.0% | 44 |
| earnings yield, 1 year ago | -25.0% | 42 |
| earnings yield, 3 years ago | -27.9% | 41 |
| earnings yield, latest year | -20.3% | 40 |
| cash flow yield, latest year | -16.7% | 39 |
| cash flow yield, 3 years ago | -14.9% | 35 |
| cash flow yield, 1 year ago | -21.0% | 32 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 21664.3% | 100 |
| debt to equity | 4.5% | 75 |
| return on equity | -34.9% | 64 |
| operating margin | -2416.1% | 10 |
4 of 4 measures available
Facts
| market cap | $657M |
| free cash flow | -$69.4M |
| employees | 196 |
| first trade | 2020-12-11 |
| next earnings | not reported |
| fundamentals updated | 2026-07-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.42 | -2.98 | -2.58 | -3.32 |
| free cash flow | -$109.6M | -$138.4M | -$78.6M | -$98.2M |
| net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M |
| revenue | $85.2M | $37,000 | $20.7M | $3.1M |